johnpaulca
12,036 posts
msg #73733
- Ignore johnpaulca |
4/21/2009 9:04:43 AM
FAZ...over $13 in pre-market
|
EWZuber
1,373 posts
msg #73735
- Ignore EWZuber |
4/21/2009 12:44:16 PM
FAZ gapped up to it's 15 DMA where it found resistance. Hourly Chart now trying to find support somewhere. Looking at the 15 or 25 HR.MA right now. The 15 HR.MA was broken but FAZ can still close above it at the top of the hour to confirm it as support.
|
johnpaulca
12,036 posts
msg #73736
- Ignore johnpaulca |
4/21/2009 1:18:10 PM
Bought back in at $9.94. We had a nice gap up this morning.
|
Radiomuse
288 posts
msg #73737
- Ignore Radiomuse |
4/21/2009 1:35:08 PM
I was short tza and faz earlier. Decent gain in faz, looks like downtrend might be reversing now.
John - you a Flames fan? I'm in Chicago so watching our teams battle it out. Actually attended a game in Calgary years ago...
|
johnpaulca
12,036 posts
msg #73738
- Ignore johnpaulca
modified |
4/21/2009 3:31:48 PM
What a game last night.... love the hit on Toews by Phaneuf.... there will be fireworks in tomorrow's game.
|
Eman93
4,750 posts
msg #73753
- Ignore Eman93
modified |
4/21/2009 9:41:47 PM
If you are not working like I will be in the am you may want to watch DYAX at 10 am.....volume has picked up in the last 3 days.........you may want to watch from the open.........option vol up also...
Nice chart in the zone
CAMBRIDGE, Mass., Apr 15, 2009 (BUSINESS WIRE) -- Dyax Corp. (DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, April 22, 2009, to discuss its financial results and company progress for the first quarter ended March 31, 2009.
Date: Wednesday, April 22, 2009
Time: 10:00 a.m. ET
Telephone Access: Domestic callers, dial 866-788-0545
International callers, dial 857-350-1683
Passcode 97354137
Online Access: Go to the Investor Relations section of the Dyax website (www.dyax.com)
and follow instructions for accessing the live webcast.
Participants may register in advance.
A replay of the conference call will be available through May 22, 2009 and may be accessed by dialing 888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 95161735. The webcast will be archived on the Dyax website for an indefinite period of time.
About Dyax
Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Dyax's lead product candidate is DX-88 (ecallantide), a recombinant small protein that is currently being evaluated for its therapeutic potential in two separate indications. On March 26, 2009, the Company received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the review of its Biologics License Application of DX-88 for the treatment of hereditary angioedema (HAE). The Company intends to respond to the FDA's requests in a timely manner. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S., for the treatment of acute attacks of HAE. Additionally, DX-88 is being evaluated in Phase 2 trials for the prevention of blood loss during on-pump cardiothoracic surgery (CTS) through Dyax's partner, Cubist Pharmaceuticals. Dyax licensed to Cubist the intravenous formulation of DX-88 for surgical indications in North America and Europe. DX-88 and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.
SOURCE: Dyax Corp.
Dyax Corp.
Ivana Magovcevic-Liebisch, 617-250-5759
Executive Vice President of Administration
and General Counsel
imagovcevic@dyax.com
or
Nicole Jones, 617-250-5744
Director, Investor Relations
njones@dyax.com
|
Eman93
4,750 posts
msg #73755
- Ignore Eman93 |
4/21/2009 10:26:52 PM
John did you pick up any BTU?
|
johnpaulca
12,036 posts
msg #73775
- Ignore johnpaulca
modified |
4/22/2009 10:15:03 AM
Eman: I will wait for price to cross lower BB40 on the weekly, then look for an entry on the hourly & 5-min chart. I had a buy signal yesterday on the hourly chart, too chicken to go long, market is slowly winding down.
|
johnpaulca
12,036 posts
msg #73776
- Ignore johnpaulca |
4/22/2009 10:22:48 AM
FAZ...will re-enter at about $8.50
|
johnpaulca
12,036 posts
msg #73778
- Ignore johnpaulca |
4/22/2009 1:14:03 PM
FAZ...will adding more at close below $9.50
|